Johnson & Johnson Acquires V-Wave For $1.7 Billion To Boost Heart Failure Treatment Portfolio‌ ‌

Global healthcare giant Johnson & Johnson (J&J) announced on Tuesday that it will acquire Israeli startup V-Wave for up to $1.7 billion, in a strategic move by J&J to bolster its position in the fast-growing congestive heart failure market, which is projected to reach $30 billion globally by 2030.

The $1.7b. deal is the 10th biggest acquisition in Israel’s history.

It will see J&J pay $600 million upfront, with an additional $1.1 billion in potential milestone payments tied to regulatory approvals and commercial performance targets. The acquisition is expected to provide a modest boost to J&J’s earnings, contributing an estimated 24 cents per share in 2024 and 6 cents per share in 2025.

However, the true value of the deal likely lies in the long-term growth potential of V-Wave’s innovative heart failure treatment technology.

V-Wave’s flagship product, the Ventura Interatrial Shunt (IAS), is an implantable device designed to alleviate the elevated left atrial pressure that plagues patients with congestive heart failure.

The minimally invasive IAS procedure aims to reduce the risk of cardiovascular events and hospitalizations for those suffering from heart failure with reduced ejection fraction – a condition where the heart muscle is unable to effectively pump blood. By creating a shunt between the left and right atriums, the device helps to relieve pressure buildup in the left atrium, potentially improving patient outcomes and quality of life.The acquisition comes at a critical time for J&J, as the company prepares to face increased competition for its blockbuster psoriasis drug Stelara, which is set to lose patent protection next year. In response, the healthcare giant has been actively pursuing mergers and acquisitions to bolster its pipeline and drive future growth.